格隆汇8月25日丨通化东宝(600867.SH)公布半年度报告，2025年上半年，归属于上市公司股东的净利润 与上年同期相比实现了扭亏为盈。实现营业收入137,349.06万元；实现利润总额25,493.19万元；实现归 属于上市公司股东的净利润21,775.81万元，同比扭亏；实现归属于上市公司股东的扣除非经常性损益的 净利润22,081.94万元。 ...

Core Viewpoint - Tonghua Dongbao Pharmaceutical Co., Ltd. reported significant growth in revenue and profit for the first half of 2025, driven by increased sales of insulin products and successful participation in national drug procurement programs [2][3]. Company Overview and Financial Indicators - The company achieved operating revenue of approximately 1.37 billion yuan, an increase of 85.60% compared to the same period last year [2]. - Total profit reached approximately 254.93 million yuan, a significant recovery from a loss in the previous year [2]. - Net profit attributable to shareholders was approximately 217.76 million yuan, marking a turnaround from a loss in the previous year [2]. - The company’s net assets decreased by 4.11% to approximately 6.12 billion yuan, while total assets increased by 6.35% to approximately 7.85 billion yuan [2]. Industry and Main Business Situation - The company operates in the pharmaceutical manufacturing industry, focusing on drug research, production, and sales, particularly in diabetes and endocrine treatment [3][4]. - The company has a comprehensive product line for diabetes treatment, including human insulin and insulin analogs, and aims to provide integrated solutions for diabetes patients [3][4]. - The company has established a strong market presence in the diabetes treatment sector, with over 40% market share in human insulin, maintaining its position as the industry leader [9][10]. Sales and Marketing Strategy - The company has implemented a specialized sales team and marketing strategies to enhance product coverage and market penetration, particularly in hospitals [12][13]. - The company successfully secured A/A1 class procurement results for its entire insulin product line, significantly increasing its hospital access and market share [14][15]. - The company is actively expanding its international market presence, with several products already approved for sale in various countries [9][10]. Research and Development - The company is committed to innovation, focusing on the development of GLP-1 receptor agonists and other novel drugs to address unmet clinical needs in diabetes and related conditions [10][11]. - The company has multiple innovative drug candidates in various stages of clinical trials, including those targeting diabetes and gout [11][18]. - The company aims to enhance its R&D capabilities and maintain a competitive edge in the pharmaceutical market through continuous innovation [10][11].

Company Overview - Tonghua Dongbao Pharmaceutical Co., Ltd. reported total assets of approximately 7.85 billion RMB at the end of the reporting period, reflecting a 6.35% increase compared to the previous year [1] - The net assets attributable to shareholders decreased by 4.11% to approximately 6.12 billion RMB [1] Financial Performance - The company achieved a revenue of approximately 1.37 billion RMB, marking an 85.60% increase year-on-year [1] - Total profit reached approximately 254.93 million RMB, a significant recovery from a loss of approximately 298.33 million RMB in the previous year [1] - The net profit attributable to shareholders was approximately 217.76 million RMB, recovering from a loss of approximately 230.49 million RMB [1] - The net cash flow from operating activities increased by 147.50% to approximately 317.36 million RMB [1] - The weighted average return on net assets was 3.35%, a turnaround from -3.32% in the previous year [1] - Basic and diluted earnings per share were both 0.11 RMB, recovering from -0.12 RMB [1] Shareholder Information - The largest shareholder, Dongbao Industrial Group Co., Ltd., holds 31.13% of the shares, amounting to approximately 609.65 million shares [2] - Other significant shareholders include Tianjin Zhenyi Equity Investment Partnership with 9.35% and Abu Dhabi Investment Authority with 1.63% [2]

Group 1 - Company achieved revenue of 1.373 billion yuan, representing a year-on-year growth of 85.60% [1] - Company reported a net profit attributable to shareholders of 218 million yuan [1] - Company operates in the pharmaceutical manufacturing industry, focusing on drug research, production, and sales [1] Group 2 - Pharmaceutical industry revenue reached 1.354 billion yuan, up from 723 million yuan in the same period last year [1] - Real estate industry revenue was 1.8557 million yuan, compared to 906,300 yuan in the same period last year [1]

Core Viewpoint - Tonghua Dongbao announced the appointment of Mr. Leng Chunsheng as the Chief Scientific Advisor of the company [2] Group 1 - The appointment was officially announced on the evening of August 25 [2]

Core Insights - Tonghua Dongbao (600867.SH) reported a revenue of 1.373 billion yuan for the first half of 2025, representing a year-on-year growth of 85.6% [1] - The company achieved a net profit attributable to shareholders of 218 million yuan, marking a turnaround from a loss to profit year-on-year [1] - The non-recurring net profit was 221 million yuan, also indicating a year-on-year turnaround to profitability [1] - Basic earnings per share stood at 0.11 yuan [1]

Core Viewpoint - Tonghua Dongbao, a leading insulin manufacturer, reported significant growth in revenue and profit for the first half of 2025, driven by the rapid increase in sales of insulin analogs and the successful implementation of national insulin procurement policies [1][2][6] Financial Performance - The company achieved a revenue of 1.373 billion yuan, representing a year-on-year increase of 85.60% [1] - Net profit attributable to shareholders reached 218 million yuan, marking a turnaround from losses [1] - The second quarter revenue was 722 million yuan, showing a quarter-on-quarter growth of 10.82% [1] Product Growth - Sales of insulin analogs increased by over 200% year-on-year, with the Aspart series insulin sales surging by over 360% [1][2] - Insulin analogs now account for over 40% of the company's total revenue, indicating a significant shift in product structure [2] Market Expansion - The company has made substantial progress in hospital access, adding approximately 1,400, 3,000, and 5,000 hospitals for different insulin products [2] - The total signed volume for insulin products in the upcoming procurement cycle is approximately 45 million units, a significant increase from 26 million units in the previous cycle [1] R&D and Innovation - R&D expenditure reached 341 million yuan, a nearly 60% increase year-on-year, reflecting the company's commitment to innovation [3] - The company is advancing multiple innovative drug candidates in the endocrine metabolism field, including GLP-1 receptor agonists and dual-target inhibitors [3][4] International Market Development - Overseas revenue reached 110 million yuan, surpassing the total for the previous year [5] - The company is actively pursuing international market opportunities, with strategic collaborations in the U.S. and sales in emerging markets like Brazil and Russia [5][6] Long-term Growth Potential - The company is positioned for sustained growth due to the increasing market share from insulin procurement, ongoing product structure optimization, and the development of innovative drug pipelines [6] - The transition from a leading insulin manufacturer to an innovator in the endocrine field is anticipated to further enhance growth prospects [6]

Core Insights - Tonghua Dongbao reported a significant increase in revenue and net profit for the first half of 2025, with revenue reaching 1.373 billion yuan, a year-on-year growth of 85.6%, and a net profit of 218 million yuan compared to a loss of 23 million yuan in the same period last year [1][2] Financial Performance - The company's revenue for the first half of 2025 was 1.373 billion yuan, marking an 85.6% increase year-on-year, primarily driven by a notable rise in sales of insulin analog products [1] - The net profit attributable to shareholders was 218 million yuan, a significant recovery from a loss of 23 million yuan in the previous year [1][2] - The net profit excluding non-recurring items was 221 million yuan, compared to a loss of 22.9 million yuan in the same period last year [1] Market Strategy and Growth - The company capitalized on the opportunities presented by the new round of centralized procurement, rapidly advancing the hospital access of its insulin series products to expand market coverage [2] - In 2024, the company achieved excellent results in the centralized procurement process, with a nearly 20 million unit increase in signed agreements compared to the first round of procurement [2] - The overseas market revenue reached 110 million yuan in the first half of 2025, reflecting a year-on-year growth of nearly 187% [2] Product Development and Collaborations - The company has established a strategic partnership with Jianyou Co., Ltd. to enter the U.S. insulin market and has met EU GMP standards for its human insulin raw material production facilities [3] - Several insulin products have received approval for sale in international markets, including Uzbekistan and Nicaragua, with ongoing registration efforts in developing countries [3] - The company is advancing the registration and application process for its GLP-1 product, liraglutide, in 17 emerging markets, having already submitted registration documents in multiple countries [3] Future Planning - The company is proactively planning future production lines for new products and is systematically advancing the construction of its biopharmaceutical production base [3] - The new production line for aspart insulin has been approved and is now in production, while the construction of the production base for liraglutide/aspart insulin is in a usable state [3]

2025年1至6月份，通化东宝的营业收入构成为：制药行业占比98.59%，其他业务占比1.27%，房地产行 业占比0.14%。 每经AI快讯，通化东宝（SH 600867，收盘价：8.61元）8月25日晚间发布公告称，公司计提信用减值损 失-353.26万元，资产减值损失2669.07万元，合计2315.81万元，减少公司2025年半年度利润总额2315.81 万元。 截至发稿，通化东宝市值为169亿元。 （记者 张喜威） 每经头条（nbdtoutiao）——A股成交连续8天破2万亿元，券商招聘也来了！行业巨头秋招"求才"，25个 岗位都有什么特点？ ...

证券代码：600867 证券简称：通化东宝 公告编号：2025-052 二、本次计提资产减值准备的具体说明 （一）信用减值损失 通化东宝药业股份有限公司 关于计提资产减值准备的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 通化东宝药业股份有限公司（以下简称"公司"）于2025年8月25日召开第十一届 董事会第十六次会议，审议通过了《关于计提资产减值准备的议案》，为了更加客观、 公正地反映公司财务状况和资产价值，根据《企业会计准则》等相关规定，结合企业实 际经营情况和资产现状，对2025年半年度相关资产进行了减值迹象的识别，对于其中已 出现减值迹象的进行了减值测试，并根据测试结果计提相关资产减值准备，现将具体情 况公告如下： 一、本次计提资产减值准备情况概述 公司根据《企业会计准则第 8 号——资产减值》《企业会计准则第 22 号——金融工 具确认和计量》等相关规定以及公司的实际业务情况，对公司 2025年半年度合并范围内 相关资产进行减值测试，根据测试结果，公司部分资产存在减值的情形，计提各项资产 减值损失2,315. ...